blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3697410

EP3697410 - BENZIMIDAZOLE DERIVATIVES AND THEIR USES [Right-click to bookmark this link]
StatusGrant of patent is intended
Status updated on  08.07.2024
Database last updated on 03.10.2024
FormerRequest for examination was made
Status updated on  28.06.2024
FormerGrant of patent is intended
Status updated on  05.03.2024
FormerRequest for examination was made
Status updated on  06.02.2024
FormerGrant of patent is intended
Status updated on  02.11.2023
FormerRequest for examination was made
Status updated on  10.10.2023
FormerGrant of patent is intended
Status updated on  01.06.2023
FormerRequest for examination was made
Status updated on  24.07.2020
FormerThe international publication has been made
Status updated on  26.04.2019
Most recent event   Tooltip08.07.2024New entry: Communication of intention to grant a patent 
Applicant(s)For all designated states
Teijin Pharma Limited
2-1, Kasumigaseki 3-chome Chiyoda-ku
Tokyo 100-0013 / JP
[2022/09]
Former [2020/35]For all designated states
Amgen Inc.
One Amgen Center
Thousand Oaks, CA 91320 / US
Inventor(s)01 / BARTBERGER, Michael D.
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
02 / CHAKKA, Nagasree
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
03 / GAO, Hua
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
04 / GUZMAN-PEREZ, Angel
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
05 / HORNE, Daniel B.
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
06 / HUA, Zihao
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
07 / KIEFFER, Madeleine
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
08 / LIN, Daniel C. H.
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
09 / MILGRAM, Benjamin Charles
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
10 / PANTELEEV, Jane
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
11 / SCHENKEL, Laurie
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
12 / STELLWAGEN, John
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
13 / WEISS, Matthew
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
14 / WHITE, Ryan D.
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
15 / ZHAO, Wei
c/o Amgen Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
 [2020/35]
Representative(s)Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
[N/P]
Former [2020/35]Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstraße 4
80802 München / DE
Application number, filing date18867844.518.10.2018
[2020/35]
WO2018US56484
Priority number, dateUS201762574465P19.10.2017         Original published format: US 201762574465 P
US201862671090P14.05.2018         Original published format: US 201862671090 P
[2020/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019079578
Date:25.04.2019
Language:EN
[2019/17]
Type: A1 Application with search report 
No.:EP3697410
Date:26.08.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 25.04.2019 takes the place of the publication of the European patent application.
[2020/35]
Search report(s)International search report - published on:US25.04.2019
(Supplementary) European search report - dispatched on:EP13.07.2021
ClassificationIPC:A61K31/40, A61K31/50, A61K31/5025, C07D487/00, C07D487/02, C07D487/04, A61P9/00, A61P11/00, A61P5/00, A61P35/00
[2021/32]
CPC:
A61P13/12 (EP,IL,KR); C07D401/14 (EP,IL,KR,US); A61K31/437 (IL,KR);
A61K31/4545 (IL,KR); A61K31/506 (IL,KR); C07D401/04 (EP,IL,KR,US);
C07D403/04 (EP,IL,KR,US); C07D405/14 (EP,IL,KR); C07D409/14 (EP,IL,KR);
C07D413/14 (EP,IL,KR,US); C07D417/14 (EP,IL,KR); C07D471/04 (EP,IL,KR,US);
C07D471/10 (EP,IL,KR,US); C07D487/02 (IL,KR); C07D487/04 (EP,IL);
C07D491/052 (EP,IL,KR); C07D491/08 (EP,IL,KR); C07D491/107 (EP,IL,KR);
C07D495/04 (EP,IL,KR); C07D498/04 (EP,IL,KR,US) (-)
Former IPC [2020/35]A61K31/40, A61K31/50, A61K31/5025, C07D487/00, C07D487/02, C07D487/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/35]
Extension statesBA05.05.2020
ME05.05.2020
Validation statesKH05.05.2020
MA05.05.2020
MD05.05.2020
TN05.05.2020
TitleGerman:BENZIMIDAZOLDERIVATE UND IHRE VERWENDUNGEN[2020/35]
English:BENZIMIDAZOLE DERIVATIVES AND THEIR USES[2020/35]
French:DÉRIVÉS DE BENZIMIDAZOLE ET LEURS UTILISATIONS[2020/35]
Entry into regional phase05.05.2020National basic fee paid 
05.05.2020Search fee paid 
05.05.2020Designation fee(s) paid 
05.05.2020Examination fee paid 
Examination procedure05.05.2020Examination requested  [2020/35]
09.02.2022Amendment by applicant (claims and/or description)
02.06.2023Communication of intention to grant the patent
09.10.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
03.11.2023Communication of intention to grant the patent
06.02.2024Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
06.03.2024Communication of intention to grant the patent
27.06.2024Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
09.07.2024Communication of intention to grant the patent
Fees paidRenewal fee
14.10.2020Renewal fee patent year 03
29.09.2021Renewal fee patent year 04
26.10.2022Renewal fee patent year 05
27.09.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]EP2368876  (SANOFI SA [FR])
International search[A]US2004106655  (KITAJIMA HIROSHI [JP], et al);
 [A]US2004152690  (BALAN CHENERA [US], et al);
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.